Literature DB >> 18781920

The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance.

Markus A Seeger1, Kay Diederichs, Thomas Eicher, Lorenz Brandstätter, André Schiefner, François Verrey, Klaas M Pos.   

Abstract

Antimicrobial resistance of human pathogenic bacteria is an emerging problem for global public health. This resistance is often associated with the overproduction of membrane transport proteins that are capable to pump chemotherapeutics, antibiotics, detergents, dyes and organic solvents out of the cell. In Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa, tripartite multidrug efflux systems extrude a large variety of cytotoxic substances from the cell membrane directly into the medium bypassing the periplasm and the outer membrane. In E. coli, the tripartite efflux system AcrA/AcrB/TolC is the pump in charge of the efflux of multiple antibiotics, dyes, bile salts and detergents. The trimeric outer membrane factor (OMF) TolC forms a beta-barrel pore in the outer membrane and exhibits a long periplasmic alpha-helical conduit. The periplasmic membrane fusion protein (MFP) AcrA serves as a linker between TolC and the trimeric resistance nodulation cell division (RND) pump AcrB, located in the inner membrane acting as a proton/drug antiporter. The newly elucidated asymmetric structure of trimeric AcrB reveals three different monomer conformations representing consecutive states in a transport cycle. The monomers show tunnels with occlusions at different sites leading from the lateral side through the periplasmic porter (pore) domains towards the funnel of the trimer and TolC. The structural changes create a hydrophobic pocket in one monomer, which is not present in the other two monomers. Minocyclin and doxorubicin, both AcrB substrates, specifically bind to this pocket substantiating its role as drug binding pocket. The energy transduction from the proton motive force into drug efflux includes proton binding in (and release from) the transmembrane part. The conformational changes observed within a triad of essential, titratable residues (Asp407/Asp408/Lys940) residing in the hydrophobic transmembrane domain appear to be transduced by transmembrane helix 8 and associated with the conformational changes seen in the periplasmic domain. From the asymmetric structure a possible peristaltic pump transport mechanism based on a functional rotation of the AcrB trimer has been postulated. The novel transport model merges Jardetzky's alternate access pump mechanism with the rotating site catalysis of F(1)F(0) ATPase and suggests a working hypothesis for the transport mechanism of RND transporters in general.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781920     DOI: 10.2174/138945008785747789

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  34 in total

1.  Coarse-grained simulations of conformational changes in the multidrug efflux transporter AcrB.

Authors:  Yead Jewel; Jin Liu; Prashanta Dutta
Journal:  Mol Biosyst       Date:  2017-09-26

2.  Analytical expressions for the homotropic binding of ligand to protein dimers and trimers.

Authors:  Scott T Lefurgy; Thomas S Leyh
Journal:  Anal Biochem       Date:  2011-12-16       Impact factor: 3.365

3.  Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop.

Authors:  Thomas Eicher; Hi-jea Cha; Markus A Seeger; Lorenz Brandstätter; Jasmin El-Delik; Jürgen A Bohnert; Winfried V Kern; François Verrey; Markus G Grütter; Kay Diederichs; Klaas M Pos
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 4.  Heavy metal transport by the CusCFBA efflux system.

Authors:  Jared A Delmar; Chih-Chia Su; Edward W Yu
Journal:  Protein Sci       Date:  2015-08-24       Impact factor: 6.725

5.  A fluorescent microplate assay quantifies bacterial efflux and demonstrates two distinct compound binding sites in AcrB.

Authors:  Ramkumar Iyer; Annette Ferrari; R Rijnbrand; Alice L Erwin
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 6.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 7.  Xenobiotic efflux in bacteria and fungi: a genomics update.

Authors:  Ravi D Barabote; Jose Thekkiniath; Richard E Strauss; Govindsamy Vediyappan; Joe A Fralick; Michael J San Francisco
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  2011

8.  Metabolic compensation of fitness costs associated with overexpression of the multidrug efflux pump MexEF-OprN in Pseudomonas aeruginosa.

Authors:  Jorge Olivares; Carolina Álvarez-Ortega; José Luis Martinez
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

9.  pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon.

Authors:  Ana Martins; Gabriella Spengler; Liliana Rodrigues; Miguel Viveiros; Jorge Ramos; Marta Martins; Isabel Couto; Séamus Fanning; Jean-Marie Pagès; Jean Michel Bolla; Joseph Molnar; Leonard Amaral
Journal:  PLoS One       Date:  2009-08-17       Impact factor: 3.240

10.  The TolC protein of Legionella pneumophila plays a major role in multi-drug resistance and the early steps of host invasion.

Authors:  Mourad Ferhat; Danièle Atlan; Anne Vianney; Jean-Claude Lazzaroni; Patricia Doublet; Christophe Gilbert
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.